Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01150760 · ClinicalTrials.gov registry record
Clinical Outcomes After Bowel Resection in Patients Receiving Alvimopan Versus Patients Not Receiving Alvimopan in the Premier Perspective Database
A clinical trial, sponsored by Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).
- Completed
- Registry status
- 7,050
- Enrollment target
NCT01150760: Completed study, sponsored by Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).
NCT01150760 is a clinical trial that has completed, run by Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA). The registered enrollment target is 7,050 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01150760 has completed, sponsored by Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).
- COMPLETED
- Registry status
- 7,050 participants
- Enrollment target
Study Summary
Alvimopan is the first and currently the only FDA-approved therapy for acceleration of the time to upper and lower gastrointestinal (GI) recovery following partial large or small bowel resection surgery with primary anastomosis. The primary objective of this retrospective observational trial is to assess postoperative morbidity and mortality as reported during the index hospitalization for bowel resection and 15/30-day readmissions of alvimopan vs. non-alvimopan matched patients in the combined Premier/Care Science database(a large medical claims database).
Primary Outcome
All-cause
Interventions
- DRUG Alvimopan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7,050 participants |
| Start Date | 2010-04 |
| Est. Completion | 2010-08 |
Sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)42 total trials
What the finished NCT01150760 record still lists
NCT01150760 is an observational study that tracks outcomes without assigning an intervention. Its 7,050 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which Alvimopan is the first listed.
NCT01150760 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01150760 about?
NCT01150760 is a clinical study titled "Clinical Outcomes After Bowel Resection in Patients Receiving Alvimopan Versus Patients Not Receiving Alvimopan in the Premier Perspective Database". Alvimopan is the first and currently the only FDA-approved therapy for acceleration of the time to upper and lower gastrointestinal (GI) recovery following partial large or small bowel resection surgery with primary anastomosis. The primary objective of this retrospective observational trial is to ...
What is the current status of trial NCT01150760?
This trial is currently completed. The enrollment target is 7,050 participants. The study started on 2010-04. Estimated completion is 2010-08.
What interventions are being tested in trial NCT01150760?
The interventions under investigation include: Alvimopan (DRUG).
Who is sponsoring clinical trial NCT01150760?
This trial is sponsored by Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), which has 42 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06843720 · 7,100 participants · NA
Expanding Access to Cervical Cancer Screening Through Primary HR-HPV Testing and Self-sampling: a Multicomponent Intervention for Safety Net Health Systems
- NCT00260585 · 7,000 participants
Esophageal Cancer Risk Registry
- NCT04118660 · 7,000 participants
Thoracic Specimen Registry
- NCT07106879 · 7,000 participants
Non-interventional Pre-screening Protocol Aims to Evaluate Participants for Potential Trial Eligibility in Future Clinical Trials/Studies Focusing on Metabolic and Psychiatric Health.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia